El interés en corto de GlycoMimetics Inc COM NEW da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de GlycoMimetics Inc COM NEW. Los datos de interés en corto se actualizan cada dos semanas.

GlycoMimetics Inc COM NEW (NASDAQ:GLYC) Bolsa, Informe de interés en corto

GlycoMimetics

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ADTX

APTO

CSAI

DSGN

EFOI

EWCZ

GLYC

GRAB

HEES

INLF

LVWR

MGOL

MTRX

NESR

NTIC

RSLS

TNMG

Las acciones de GCL Global suben más del 100% en premercado tras su fusión. Descubre qué otras acciones están en movimiento hoy.

Acciones de GCL Global Holdings (GCL) se disparan un 107%; 20 acciones que se mueven en el premercado

GlycoMimetics Inc COM NEW

U.S. stock futures were lower this morning, with the Dow futures falling around 0.2% points on Wednesday.
Shares of GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) fell sharply in today's pre-market trading as the company posted results <a href="https://www.benzinga.com/quote/GME/earnings">for its first quarter.</a>
GameStop reported first-quarter revenue of $732.4 million, missing analyst estimates of $754.24 million. The company reported first-quarter adjusted earnings of 17 cents per share, beating analyst estimates of four cents per share, according to Benzinga Pro.
GameStop shares dipped 4.9% to $28.68 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>American Superconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMSC#NASDAQ">AMSC</a>) shares dipped 14.3% to $29.54 in pre-market trading after the company announced a proposed public offering of common stock.</li>
<li>GlycoMimetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) fell 13.4% to $0.1475 in pre-market trading.</li>
<li>GitLab Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>) fell 12.4% to $42.50 in pre-market trading after the company reported first-quarter financial results and issued second-quarter sales guidance with its midpoint below estimates.</li>
<li>Arrive AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAI#NASDAQ">ARAI</a>) shares dipped 9% to $9.33 in pre-market trading. Arrive AI shares jumped over 62% on Tuesday after the company announced it obtained another patent for its AI-powered smart mailbox platform designed for autonomous and conventional package delivery.</li>
<li>Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) declined 7.9% to $8.16 in pre-market trading.</li>
<li>Twin Hospitality Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWNP#NASDAQ">TWNP</a>) dipped 7.8% to $5.93 in pre-market trading.</li>
<li>Cleveland-Cliffs Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) declined 7.4% to $7.44 in pre-market trading. Shares of steel companies moved lower following reports the U.S. and Mexico are nearing a deal that would remove the Trump Administration's tariffs on steel imports.</li>
<li>Tenet Healthcare Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) fell 7% to $145.50 in pre-market trading after declining more than 5% on Tuesday.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45858699/top-2-tech-and-telecom-stocks-you-may-want-to-dump-in-q2">Top 2 Tech And Telecom Stocks You May Want To Dump In Q2</a> </li>
</ul>
Photo via Shutterstock

AMSC

ARAI

GTLB

TWNP

GameStop Posts Weak Revenue, Joins American Superconductor, GitLab And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Shares of Stitch Fix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFIX#NASDAQ">SFIX</a>) rose sharply in today's pre-market trading after the company posted <a href="https://www.benzinga.com/quote/FIX/earnings">better-than-expected results for its third quarter.</a>
Stitch Fix reported quarterly losses of six cents per share, which beat the analyst consensus estimate of losses of 11 cents per share. Quarterly revenue came in at $325.02 million, beating the $314.44 million consensus estimate.
Stitch Fix shares jumped 8.4% to $5.19 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>Catheter Precision, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#NYSE">VTAK</a>) surged 101.9% to $0.46 in pre-market trading after the company received CE Mark approval for advanced vascular closure device LockeT.</li>
<li>INNEOVA Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INEO#NASDAQ">INEO</a>) shares jumped 81.9% to $2.11 in pre-market trading.</li>
<li>FST Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KBSX#NASDAQ">KBSX</a>) jumped 61% to $2.51 in pre-market trading.</li>
<li>Vaxart, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VXRT#NASDAQ">VXRT</a>) gained 49.7% to $0.5877 in pre-market trading after it said that it will reveal the first-ever oral norovirus vaccine trial results on Wednesday.</li>
<li>ZW Data Action Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNET#NASDAQ">CNET</a>) climbed 41.5% to $1.79 in pre-market trading after the company announced it issued 358,424 restricted shares to investors for $3.00 per share with the total gross proceeds amounting to approximately $1,075,272</li>
<li>NuCana plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) rose 38.5% to $0.1988 in pre-market trading after jumping 88% on Tuesday.</li>
<li>Imunon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) rose 16.1% to $1.88 in pre-market trading after jumping 22% on Tuesday.</li>
<li>YSX Tech. Co., Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YSXT#NASDAQ">YSXT</a>) surged 12.7% to $5.70 in pre-market trading.</li>
<li>Getty Images Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GETY#NYSE">GETY</a>) gained 10.7% to $1.87 in pre-market trading. At a special meeting on Tuesday, Shutterstock's shareholders approved the adoption of the merger agreement between the company and Getty Images, with approximately 82% voting in favor.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>Graphjet Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTI#NASDAQ">GTI</a>) shares tumbled 37.3% to $0.0545 in pre-market trading after receiving a delisting notice from Nasdaq on June 4.</li>
<li>Carisma Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARM#NASDAQ">CARM</a>) dipped 32.5% to $0.7505 in pre-market trading after jumping 389% on Tuesday.</li>
<li>Senmiao Technology Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIHS#NASDAQ">AIHS</a>) shares fell 18.7% to $1.14 in pre-market trading after jumping 28% on Tuesday.</li>
<li>Gelteq Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GELS#NASDAQ">GELS</a>) declined 18% to $2.42 in pre-market trading. Gelteq shares jumped 79% on Tuesday after the company announced it expanded its U.S. commercial strategy through an exclusive logistics and distribution agreement with Healthy Extracts.</li>
<li>Draganfly Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPRO#NASDAQ">DPRO</a>) declined 17.5% to $3.06 in pre-market trading after gaining 11% on Tuesday.</li>
<li>American Superconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMSC#NASDAQ">AMSC</a>) fell 14.3% to $29.54 in pre-market trading after the company announced a proposed public offering of common stock.</li>
<li>GlycoMimetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) dipped 13.4% to $0.1475 in pre-market trading.</li>
<li>GitLab Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>) declined 12.4% to $42.50 in pre-market trading after the company reported first-quarter financial results and issued second-quarter sales guidance with its midpoint below estimates.</li>
<li>Arrive AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAI#NASDAQ">ARAI</a>) fell 9% to $9.33 in pre-market trading. Arrive AI shares jumped over 62% on Tuesday after the company announced it obtained another patent for its AI-powered smart mailbox platform designed for autonomous and conventional package delivery</li>
<li>Cleveland-Cliffs Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) fell 7.4% to $7.44 in pre-market trading. Shares of steel companies moved lower following reports the U.S. and Mexico are nearing a deal that would remove the Trump Administration's tariffs on steel imports.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45858699/top-2-tech-and-telecom-stocks-you-may-want-to-dump-in-q2"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45858699/top-2-tech-and-telecom-stocks-you-may-want-to-dump-in-q2">Top 2 Tech And Telecom Stocks You May Want To Dump In Q2</a> </li>
</ul>
Photo via Shutterstock

AIHS

CARM

CNET

DPRO

GELS

GETY

IMNN

INEO

KBSX

NCNA

SFIX

VTAK

VXRT

YSXT

Why Stitch Fix Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket

<h3>Gainers</h3>
<ul>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) shares rose 142.0% to $0.5 during Monday's pre-market session. The market value of their outstanding shares is at $16.1 million. </li>
<li>Know Labs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KNW#AMEX">KNW</a>) shares moved upwards by 103.2% to $3.17. The market value of their outstanding shares is at $23.7 million. </li>
<li>Tempest Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPST#NASDAQ">TPST</a>) stock increased by 30.37% to $10.75. The company's market cap stands at $39.5 million. </li>
<li>Metsera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSR#NASDAQ">MTSR</a>) stock increased by 16.4% to $32.0. The company's market cap stands at $3.3 billion. </li>
<li>Jade Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBIO#NASDAQ">JBIO</a>) stock moved upwards by 14.32% to $8.22. The company's market cap stands at $432.3 million. </li>
<li>BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) shares increased by 12.71% to $6.47. The market value of their outstanding shares is at $24.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Kalaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLRS#NASDAQ">KLRS</a>) shares declined by 23.9% to $2.51 during Monday's pre-market session. The company's market cap stands at $46.9 million. </li>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) shares declined by 15.28% to $20.52. The company's market cap stands at $533.8 million. </li>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) stock decreased by 13.77% to $0.94. </li>
<li>SILO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) shares fell 13.55% to $0.5. The market value of their outstanding shares is at $3.6 million. </li>
<li>GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) stock declined by 9.91% to $0.17. The market value of their outstanding shares is at $11.2 million. </li>
<li>Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) stock declined by 8.28% to $0.72. The company's market cap stands at $56.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BLRX

CLSD

HSDT

JBIO

KLRS

KLTO

LIMN

MTSR

SILO

Tempest Therapeutics, Inc. - Common Stock

TPST

12 Health Care Stocks Moving In Monday's Pre-Market Session

GlycoMimetics's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NYSE">GLYC</a>) short percent of float has fallen 8.14% since its last report. The company recently reported that it has 1.68 million shares sold short, which is 3.16% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.71 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>GlycoMimetics Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749229230_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for GlycoMimetics has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing GlycoMimetics's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, GlycoMimetics's peer group average for short interest as a percentage of float is 2.98%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

What Does the Market Think About GlycoMimetics?

<h3>Gainers</h3>
<ul>
<li>Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) stock rose 41.5% to $2.15 during Thursday's after-market session. The market value of their outstanding shares is at $3.2 million. </li>
<li>GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) shares moved upwards by 30.86% to $0.26. The company's market cap stands at $16.7 million. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) shares increased by 28.97% to $4.05. The company's market cap stands at $11.6 million. </li>
<li>Pediatrix Medical Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MD#NYSE">MD</a>) shares moved upwards by 8.47% to $15.1. The company's market cap stands at $1.2 billion. </li>
<li>Rani Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RANI#NASDAQ">RANI</a>) shares increased by 7.27% to $0.57. The company's market cap stands at $19.0 million. </li>
<li>RAPT Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPT#NASDAQ">RAPT</a>) stock rose 6.86% to $1.09. The company's market cap stands at $144.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) shares declined by 18.7% to $20.0 during Thursday's after-market session. The company's market cap stands at $534.2 million. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) shares decreased by 10.12% to $3.2. The market value of their outstanding shares is at $83.4 million. </li>
<li>Pheton Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTHL#NASDAQ">PTHL</a>) shares decreased by 9.44% to $8.06. The market value of their outstanding shares is at $116.8 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) stock fell 8.15% to $3.86. The company's market cap stands at $58.7 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares decreased by 7.83% to $2.12. The market value of their outstanding shares is at $1.5 million. </li>
<li>Scinai Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) shares declined by 7.7% to $3.0. The company's market cap stands at $2.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BJDX

EYEN

NIVF

PTHL

RANI

RAPT

SCNI

SNTI

12 Health Care Stocks Moving In Thursday's After-Market Session

WIIM

GlycoMimetics shares are trading higher after the company approved the proposed merger with Crescent Biopharma and announced a 1-for-100 reverse stick split.

GlycoMimetics Stockholders Approve Merger With Crescent Biopharma

Stock Split

GlycoMimetics Board Of Directors Approves 1-For-100 Reverse Stock Split

<h3>Gainers</h3>
<ul>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) shares increased by 13.7% to $0.99 during Thursday's pre-market session. The market value of their outstanding shares is at $4.3 million. </li>
<li>GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) shares increased by 13.32% to $0.27. The company's market cap stands at $17.4 million. </li>
<li>Avanos Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVNS#NYSE">AVNS</a>) stock rose 12.55% to $13.99. The market value of their outstanding shares is at $643.5 million. </li>
<li>Community Health Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYH#NYSE">CYH</a>) shares moved upwards by 11.11% to $2.7. The market value of their outstanding shares is at $375.0 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>NovoCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCR#NASDAQ">NVCR</a>) shares rose 8.49% to $19.28. The market value of their outstanding shares is at $2.1 billion. As per the press release, Q1 earnings came out today. </li>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares rose 8.2% to $0.86. The company's market cap stands at $4.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Forian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORA#NASDAQ">FORA</a>) shares decreased by 32.6% to $1.26 during Thursday's pre-market session. The company's market cap stands at $39.3 million. </li>
<li>X4 Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XFOR#NASDAQ">XFOR</a>) stock decreased by 23.45% to $0.15. The company's market cap stands at $26.7 million. </li>
<li>Relmada Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLMD#NASDAQ">RLMD</a>) stock fell 22.44% to $0.54. The company's market cap stands at $17.7 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares declined by 15.26% to $3.11. The market value of their outstanding shares is at $5.1 million. </li>
<li>Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) shares decreased by 13.05% to $6.0. The market value of their outstanding shares is at $35.1 million. </li>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) stock decreased by 12.68% to $1.24. The market value of their outstanding shares is at $3.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATRA

AVNS

CERO

ENSC

FORA

NUWE

NVCR

RLMD

SONN

XFOR

12 Health Care Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Sonoma Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNOA#NASDAQ">SNOA</a>) shares increased by 98.3% to $4.62 during Wednesday's pre-market session. The market value of their outstanding shares is at $7.4 million. </li>
<li>GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) stock moved upwards by 25.91% to $0.29. The market value of their outstanding shares is at $18.3 million. </li>
<li>ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) stock rose 24.78% to $3.85. The company's market cap stands at $2.0 million. </li>
<li>Forte Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBRX#NASDAQ">FBRX</a>) shares rose 22.62% to $8.4. The market value of their outstanding shares is at $53.7 million. </li>
<li>Rezolute (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLT#NASDAQ">RZLT</a>) stock rose 21.28% to $3.77. The company's market cap stands at $228.3 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares increased by 17.11% to $2.19. The company's market cap stands at $3.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Serina Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SER#AMEX">SER</a>) stock fell 21.6% to $4.31 during Wednesday's pre-market session. The company's market cap stands at $42.8 million. </li>
<li>Gelteq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GELS#NASDAQ">GELS</a>) stock declined by 17.37% to $2.38. The market value of their outstanding shares is at $22.4 million. </li>
<li>NeOnc Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTHI#NASDAQ">NTHI</a>) shares decreased by 16.39% to $5.0. The market value of their outstanding shares is at $112.8 million. </li>
<li>Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) stock fell 15.26% to $5.11. The company's market cap stands at $43.7 million. </li>
<li>Intensity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>) stock decreased by 13.62% to $1.65. The market value of their outstanding shares is at $25.0 million. </li>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) shares declined by 12.46% to $0.05. The market value of their outstanding shares is at $1.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FBRX

INTS

KPTI

NDRA

NTHI

PTPI

RZLT

SNOA

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Crescent also appointed Jonathan McNeill, president and chief operating officer; Ellie Im, M.D., chief medical officer; Rick Scalzo, MBA, chief financial officer; and Amy Reilly, chief communications officer.

Management

GlycoMimetics Merger-Bound Crescent Appoints Joshua Brumm As CEO

Cantor Fitzgerald analyst Eric Schmidt initiates coverage on GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) with a Overweight rating.

Initiation

Analyst Ratings

Cantor Fitzgerald Initiates Coverage On GlycoMimetics with Overweight Rating

<h3>Gainers</h3>
<ul>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares increased by 81.7% to $0.87 during Tuesday's pre-market session. The company's market cap stands at $4.9 million. </li>
<li>GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) stock rose 35.65% to $0.39. The company's market cap stands at $25.3 million. The company's, Q4 earnings came out 3 days ago. </li>
<li>Innate Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPHA#NASDAQ">IPHA</a>) shares rose 33.5% to $2.59. The market value of their outstanding shares is at $217.0 million. </li>
<li>Aditxt (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) shares moved upwards by 30.85% to $0.09. The market value of their outstanding shares is at $7.2 million. </li>
<li>GeneDx Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>) shares moved upwards by 18.0% to $90.1. The market value of their outstanding shares is at $2.4 billion. The company's, Q4 earnings came out today. </li>
<li>Camp4 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>) stock moved upwards by 17.25% to $5.98. The company's market cap stands at $120.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) shares fell 57.1% to $1.0 during Tuesday's pre-market session. </li>
<li>Bio-Path Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) shares fell 33.2% to $0.42. The market value of their outstanding shares is at $2.4 million. </li>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) shares decreased by 24.92% to $0.22. The company's market cap stands at $2.4 million. </li>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) shares decreased by 16.8% to $0.27. The market value of their outstanding shares is at $4.9 million. </li>
<li>Moleculin Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) shares decreased by 15.6% to $1.84. The company's market cap stands at $6.2 million. </li>
<li>Omega Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMGA#NASDAQ">OMGA</a>) stock declined by 14.8% to $0.2. The market value of their outstanding shares is at $10.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BPTH

CAMP

HCTI

IPHA

MBRX

OMGA

VRPX

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Shares of GCL Global Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCL#NASDAQ">GCL</a>) rose sharply in today&#8217;s pre-<a href="https://www.benzinga.com/quote/GCL">market trading</a>.
GCL and RF Acquisition Corp. disclosed the successful completion of their business combination.
GCL Global shares jumped 107.1% to $6.13 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Energy Focus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFOI#NASDAQ">EFOI</a>) rose 70% to $2.21 in pre-market trading after gaining over 5% on Friday.</li>
<li>GlycoMimetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) shares jumped 53.1% to $0.4442 in pre-market trading. GlycoMimetics and Crescent amended merger agreement.</li>
<li>Aditxt, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) gained 30.1% to $0.0915 in pre-market trading after reporting financial and operational results for third quarter of fiscal year 2025.</li>
<li>Pagaya Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGY#NASDAQ">PGY</a>) gained 23.3% to $18.95 in pre-market trading. Pagaya Technologies, last week, reported better-than-expected quarterly financial results.</li>
<li>TNL Mediagene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNMG#NASDAQ">TNMG</a>) gained 21.4% to $2.99 in pre-market trading after declining around 4% on Friday.</li>
<li>H&amp;E Equipment Services, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEES#NASDAQ">HEES</a>) gained 21.2% to $106.00 in pre-market trading.</li>
<li>Cloudastructure Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSAI#NASDAQ">CSAI</a>) shares climbed 18.7% to $22.61 in pre-market trading after dipping 49% on Friday.</li>
<li>Aptose Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) gained 17.8% to $0.2120 in pre-market. Aptose, last week, entered into $25 million committed equity facility and enters at-the-market distributions.</li>
<li>Grab Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRAB#NYSE">GRAB</a>) rose 14.3% to $5.60 in pre-market trading. Soros Fund Management dissolved share stake in Grab Holdings.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>ReShape Lifesciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) shares fell 60.4% to $0.9199 in pre-market trading after the company reported the pricing of upsized $6.0 million public offering.</li>
<li>Design Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGN#NASDAQ">DSGN</a>) shares fell 50.7% to $2.01 in pre-market trading.</li>
<li>Northern Technologies International Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTIC#NASDAQ">NTIC</a>) dipped 37.5% to $7.00 in pre-market trading.</li>
<li>Matrix Service Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTRX#NASDAQ">MTRX</a>) fell 30.2% to $10.61 in pre-market trading.</li>
<li>European Wax Center, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWCZ#NASDAQ">EWCZ</a>) fell 27.7% to $5.31 in today's pre-market trading.</li>
<li>INLIF Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INLF#NASDAQ">INLF</a>) fell 26.4% to $12.02 in pre-market trading after jumping 81% on Friday.</li>
<li>MGO Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGOL#NASDAQ">MGOL</a>) shares tumbled 25.2% to $0.5370 in pre-market trading. MGO Global&#8217;s stockholders approved business combination with Heidmar.</li>
<li>National Energy Services Reunited Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NESR#NASDAQ">NESR</a>) declined 23.7% to $7.20 in pre-market trading.</li>
<li>LiveWire Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVWR#NASDAQ">LVWR</a>) fell 22.5% to $2.02 in pre-market trading.</li>
<li>Emerald Holding, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EEX#NYSE">EEX</a>) shares dipped 10.7% to $3.9100 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43730195/top-3-defensive-stocks-that-may-collapse-in-q1">Top 3 Defensive Stocks That May Collapse In Q1</a></li>
</ul>

Why GCL Global Holdings Shares Are Trading Higher By Around 107%; Here Are 20 Stocks Moving Premarket

Offerings

GlycoMimetics And Crescent Amend Merger Agreement; Crescent To Own 96.90% Post-Merger; $200M Securities Purchase Reallocated; Ownership And Exchange Ratio Unchanged; $1.8M Net Cash At Closing

<h3>Gainers</h3>
<ul>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares increased by 21.6% to $0.5 during Wednesday's pre-market session. The company's market cap stands at $7.5 million. </li>
<li>CalciMedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALC#NASDAQ">CALC</a>) stock rose 18.32% to $4.65. The company's market cap stands at $49.9 million. </li>
<li>Matinas BioPharma Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MTNB#AMEX">MTNB</a>) shares increased by 18.27% to $3.3. The company's market cap stands at $16.5 million. </li>
<li>AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) stock increased by 15.52% to $34.0. The market value of their outstanding shares is at $1.6 billion. The company's, Q3 earnings came out yesterday. </li>
<li>Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) stock rose 15.38% to $1.95. The market value of their outstanding shares is at $117.4 million. </li>
<li>HOOKIPA Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOK#NASDAQ">HOOK</a>) shares increased by 14.47% to $4.27. The company's market cap stands at $42.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) stock fell 41.7% to $0.18 during Wednesday's pre-market session. The market value of their outstanding shares is at $1.9 million. </li>
<li>AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) shares fell 21.43% to $24.2. The company's market cap stands at $730.8 million. </li>
<li>Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) stock decreased by 19.85% to $1.05. The market value of their outstanding shares is at $56.7 million. </li>
<li>GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) stock fell 14.31% to $0.42. The market value of their outstanding shares is at $27.0 million. </li>
<li>Tempest Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPST#NASDAQ">TPST</a>) shares declined by 13.65% to $0.95. The company's market cap stands at $23.9 million. </li>
<li>CVRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVRX#NASDAQ">CVRX</a>) shares fell 11.92% to $9.46. The market value of their outstanding shares is at $205.3 million. As per the news, the Q3 earnings report came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANAB

APDN

ATRC

CALC

CVRX

HOOK

MTNB

SPRO

<h3>Gainers</h3>
<ul>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock increased by 21.4% to $0.5 during Wednesday's pre-market session. The company's market cap stands at $7.5 million. </li>
<li>AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) stock increased by 18.92% to $35.0. The company's market cap stands at $1.7 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li>CalciMedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALC#NASDAQ">CALC</a>) stock increased by 18.32% to $4.65. The market value of their outstanding shares is at $49.9 million. </li>
<li>Matinas BioPharma Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MTNB#AMEX">MTNB</a>) stock moved upwards by 18.27% to $3.3. The company's market cap stands at $16.5 million. </li>
<li>Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) stock rose 15.38% to $1.95. The company's market cap stands at $117.4 million. </li>
<li>HOOKIPA Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOK#NASDAQ">HOOK</a>) stock rose 14.47% to $4.27. The company's market cap stands at $42.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) shares fell 42.2% to $0.18 during Wednesday's pre-market session. The company's market cap stands at $1.8 million. </li>
<li>AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) shares decreased by 21.43% to $24.2. The market value of their outstanding shares is at $730.8 million. </li>
<li>Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) shares fell 19.12% to $1.06. The market value of their outstanding shares is at $57.2 million. </li>
<li>GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) stock declined by 15.94% to $0.41. The company's market cap stands at $26.5 million. </li>
<li>Tempest Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPST#NASDAQ">TPST</a>) stock declined by 14.13% to $0.94. The company's market cap stands at $23.8 million. </li>
<li>CVRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVRX#NASDAQ">CVRX</a>) stock fell 11.92% to $9.46. The company's market cap stands at $205.3 million. As per the news, the Q3 earnings report came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Shares of Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) rose sharply in today's pre-market trading after the company reported better-than-expected<a href="https://www.benzinga.com/news/earnings/24/10/41611263/alphabet-q3-earnings-highlights-revenue-beat-eps-beat-google-cloud-up-35-momentum-across-the-compan"> third-quarter financial results</a>.
The company reported third-quarter revenue of $88.27 billion, up 15% year-over-year. The total beat a Street consensus estimate of $86.31 billion
Alphabet shares jumped 6% to $179.77 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Haoxi Health Technology Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAO#NASDAQ">HAO</a>) gained 82.8% to $0.3382 in pre-market trading. Haoxi Health Technology recently posted FY earnings of 4 cents per share.</li>
<li>Starbox Group Holdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STBX#NASDAQ">STBX</a>) rose 80.2% to $0.2433 in pre-market trading.</li>
<li>Digital Brands Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBGI#NASDAQ">DBGI</a>) shares surged 50.5% to $0.1540 in pre-market trading. Digital Brands Group shares fell around 34% on Tuesday after the company announced the pricing of $3 million public offering of 30 million common stock and pre-funded warrants at $0.10 per share.</li>
<li>Ensysce Biosciences, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) gained 30.8% to $0.5430 in pre-market trading after jumping around 25% on Tuesday.</li>
<li>NerdWallet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRDS#NASDAQ">NRDS</a>) shares rose 28.7% to $14.57 in pre-market trading after the company reported better-than-expected fourth-quarter revenue results.</li>
<li>LogicMark, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) climbed 26.4% to $0.1464 in pre-market trading.</li>
<li>Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) gained 24% to $101.36 in pre-market trading after the company reported better-than-expected third-quarter financial results and issued fourth-quarter revenue guidance above estimates.</li>
<li>Polyrizon Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares gained 20.7% to $1.87 in pre-market trading after dipping 65% on Tuesday. The company priced its IPO at $4.38 per unit.</li>
<li>Snap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) shares rose 11.2% to $12.11 in pre-market trading following better-than-expected third-quarter financial results.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>O-I Glass, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OI#NYSE">OI</a>) shares dipped 18.4% to $10.15 in pre-market trading after the company reported worse-than-expected third-quarter financial results and issued FY24 adjusted EPS guidance below estimates.</li>
<li>Spero Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) shares fell 18.3% to $1.07 in pre-market trading after the company announced its Phase 2a proof-of-concept study of SPR720 did not meet its primary endpoint.</li>
<li>Qorvo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>) shares fell 18% to $82.40 in pre-market trading after the company reported issued weak guidance for the third quarter.</li>
<li>GlycoMimetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) fell 14.5% to $0.4189 in today's pre-market trading. GlycoMimetics shares jumped 191% on Tuesday after the company announced it will merge with Crescent Biopharma and secured $200 in funding to advance its oncology pipeline.</li>
<li>Thryv Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRY#NASDAQ">THRY</a>) fell 13.7% to $15.80 in pre-market trading after the company priced its upsized $80 million public offering of 5,715,000 common shares at $14/share.</li>
<li>Tempest Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPST#NASDAQ">TPST</a>) fell 12.3% to $0.9645 in pre-market trading. The company recently entered into an agreement with Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) to advance the evaluation of amezalpat (TPST-1120) in combination with atezolizumab (Tecentriq) and bevacizumab, the current standard of care for unresectable or metastatic hepatocellular carcinoma (HCC), into a Phase 3 trial for the first-line treatment of liver cancer.</li>
<li>Ambow Education Holding Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMBO#NYSE">AMBO</a>) shares declined 12.3% to $1.50 in pre-market trading.</li>
<li>Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) declined 12.2% to $1.58 in pre-market trading as the company priced its $4.5 million public offering of 2,950,820 at-the-market under Nasdaq rules.</li>
<li>Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) shares fell 8.6% to $152.00 after the company reported third-quarter financial results.</li>
<li>Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) fell 8.4% to $47.17 in pre-market trading after gaining around 9% on Tuesday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41599928/top-3-tech-and-telecom-stocks-which-could-rescue-your-portfolio-for-october">Top 3 Tech And Telecom Stocks Which Could Rescue Your Portfolio For October</a></li>
</ul>

AMBO

DBGI

GOOG

GOOGL

LGMK

NRDS

PLRZ

QRVO

RDDT

RHHBY

SHPH

SNAP

STBX

THRY

Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket

U.S. stocks traded mostly higher toward the end of trading, with the Nasdaq Composite gaining more than 150 points on Tuesday.
The Dow traded down 0.11% to 42,341.64 while the NASDAQ rose 0.85% to 18,724.32. The S&amp;P 500 also rose, gaining, 0.35% to 5,843.93.
Check This Out: <a href="https://www.benzinga.com/news/24/10/41598310/jim-cramer-avoid-this-consumer-cyclical-stock-buy-lam-research">Jim Cramer: &#8216;Avoid&#8217; This Consumer Cyclical Stock, Buy Lam Research</a>
Leading and Lagging Sectors Communication services shares rose by 1.5% on Tuesday.
In trading on Tuesday, utilities shares fell by 1.8%.
Top Headline
Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) shares fell around 5% on Tuesday after it reported third-quarter FY24 results.
Adjusted EPS of $2.04 topped the consensus of $1.66. Midstream segment adjusted pre-tax income stood at $672 million, vs. $753 million in the second quarter of FY24, owing to seasonal maintenance costs and lower equity earnings.
The Chemicals segment adjusted pre-tax income stood at $342 million versus $222 million in the prior quarter, led by higher margins and lower costs.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>GlycoMimetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) shares shot up 172% to $0.4608 after the company announced it will merge with Crescent Biopharma and secured $200 in funding to advance its oncology pipeline.</li>
<li>Shares of BIO-key International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKYI#NASDAQ">BKYI</a>) got a boost, surging 60% to $1.08 after the company announced it received a $910K order from a long-time financial services customer to upgrade its biometric customer identification technology.</li>
<li>GeneDx Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>) shares were also up, gaining 46% to $81.57 after the company reported better-than-expected third-quarter financial results and raised its FY24 revenue guidance.</li>
</ul>
Equities Trading DOWN
<ul>
<li>1847 Holdings LLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#NASDAQ">EFSH</a>) shares dropped 63% to $0.4655 after the company priced an $11.1 million public offering at $1.26 per unit.</li>
<li>Shares of TransMedics Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) were down 31% to $87.61 after the company reported worse-than-expected third-quarter financial results and issued FY24 revenue guidance with its midpoint below estimates.</li>
<li>Janus International Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBI#NYSE">JBI</a>) was down, falling 32% to $7.00 after the company reported worse-than-expected third-quarter financial results and cut its FY24 sales guidance below estimates.</li>
</ul>
Commodities In commodity news, oil traded down 0.1% to $67.36 while gold traded up 1% at $2,782.00.
Silver traded up 1.5% to $34.50 on Tuesday, while copper fell 0.1% to $4.3595.
Euro zone
European shares closed lower today. The eurozone's STOXX 600 slipped 0.57%, Germany's DAX fell 0.27% and France's CAC 40 slipped 0.61%. Spain's IBEX 35 Index fell 0.91%, while London's FTSE 100 fell 0.80%.
Asia Pacific Markets
Asian markets closed mixed on Tuesday, with Japan's Nikkei 225 gaining 0.77%, Hong Kong's Hang Seng Index gaining 0.49%, China's Shanghai Composite Index falling 1.08% and India's BSE Sensex surging 0.45%.
Economics
<ul>
<li>The number of job openings declined by 418,000 to 7.443 million in September versus a revised 7.861 million in the previous month and below market estimates of 7.99 million.</li>
<li>The FHFA house price index rose 0.3% in August, above market estimates of a 0.2% rise.</li>
<li>The S&amp;P CoreLogic Case-Shiller home price index rose 5.2% year-over-year in August versus a 5.9% gain in July.</li>
<li>U.S. wholesale inventories declined by 0.1% month-over-month to $905 billion in September compared to revised 0.2% gain in the earlier month.</li>
<li>The U.S. trade deficit increased to $108.2 billion in September from the $94.2 billion gap in the previous month.</li>
<li>The Dallas Fed general business activity index for Texas&#8217; service sector climbed to 2 in October compared to a reading of -2.6 in the prior month.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41598309/wall-streets-most-accurate-analysts-give-their-take-on-3-consumer-stocks-delivering-high-dividend-yi">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Consumer Stocks Delivering High-Dividend Yields</a></li>
</ul>

Earnings

Equities

Eurozone

Commodities

BKYI

EFSH

TMDX

Gold Gains 1%; Phillips 66 Shares Fall After Q3 Results

GlycoMimetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) shares are moving higher on Tuesday after the company announced it will merge with Crescent Biopharma. The company also said it secured $200 million in funding to advance <a href="https://www.benzinga.com//node/41595830">its oncology pipeline</a>.
What To Know: GlycoMimetics has entered into an acquisition agreement with privately held biotech firm Crescent BioPharma. The combined company, which will operate under the name Crescent Biopharma, Inc., will focus on advancing Crescent Biopharma's current solid tumor portfolio, including its lead therapies CR-001, CR-002 and CR-003.
In support of the merger, a group of investors has agreed to purchase $200 million in the combined company&#8217;s common stock and pre-funded warrants. The purpose of the funding is to support operations through 2027, including further developing lead therapeutic treatments.
The merger transaction is anticipated to close in the second quarter of 2025, with the financing transaction expected to close immediately afterward.
Under the acquisition agreement, pre-acquisition GlycoMimetics stockholders will hold about 3.1% of the combined company, while pre-acquisition Crescent stockholders, including those involved in pre-closing financing, will own roughly 96.9%.
&#8220;We are confident that our transaction with Crescent represents a significant opportunity for GlycoMimetics and its stockholders,&#8221; said Harout Semerjian, CEO of GlycoMimetics. 
&#8220;This transaction is the result of a comprehensive strategic review, and with additional funding for Crescent&#8217;s portfolio of novel biologics, we believe the company is well-positioned to carry forward the mission of seeking to improve the lives of patients.&#8221;
GlycoMimetics stock is trading on above-average volume Tuesday. The company&#8217;s average session volume over the past 100 days is 1.05 million, but Tuesday&#8217;s trading volume was around 856 million at the time of publication. 
Related Link: <a href="https://www.benzinga.com/news/24/10/41582814/whats-going-on-with-boeing-stock-monday">What&#8217;s Going On With Boeing Stock Monday?</a>
GLYC Price Action: At the time of publication, GlycoMimetics shares are up 210.1% at 52 cents, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Image: Akava Photo from Pixabay

GlycoMimetics Shares Are Soaring Tuesday: Here's Why

Press Releases

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders

Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics

Crescent Biopharma Appoints David Lubner to Board of Directors

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates COLB, PRA, GLYC on Behalf of Shareholders

Small Cap

$TOCKHOLDER ALERT: The M&A Class Action Firm Continues Its Investigation Into The Merger - GLYC, BRZH, PRA, FVNNU

Legal

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PRA, FARO, AVDX, GLYC on Behalf of Shareholders

GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYC

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDFN, LRFC, RDW, GLYC on Behalf of Shareholders

Health Care

Crescent Biopharma to Present at the Jefferies Global Healthcare Conference

GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals

Comments

GlycoMimetics Inc COM NEW

Interés en corto

GlycoMimetics Inc COM NEW (NASDAQ:GLYC) Bolsa, Informe de interés en corto

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL